1-9 of 9
Laurence Elias, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 31.
https://doi.org/10.1182/blood.V124.21.31.31
Published: 2014
Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2012) 120 (21): 4039.
https://doi.org/10.1182/blood.V120.21.4039.4039
Published: 2012
Journal Articles

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Yu-Tzu Tai, PhD, Betty Y Chang, PhD, Sun-Young Kong, MD, PhD, Mariateresa Fulciniti, PhD, Guang Yang, PhD, Yolanda Calle, PhD, Yiguo Hu, MD, PhD, Jianhong Lin, PhD, Jian-Jun Zhao, PhD, Michele Cea, MD, Antonia Cagnetta, MD, Michael A Sellitto, BS, Michelle Chen, Zachary Hunter, BS, Ruben Carrasco, MD, PhD, Joseph J. Buggy, PhD, Laurence Elias, MD, William Matsui, MD, Steven P Treon, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 883.
https://doi.org/10.1182/blood.V118.21.883.883
Published: 2011
Journal Articles

Egress of CD19 + CD5 + Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Betty Y Chang, PhD, Michelle Francesco, Padmaja Magadala, Min Mei Huang, PhD, Marcel Spaargaren, PhD, Joseph J. Buggy, PhD, Laurence Elias, MD
Journal: Blood
Blood (2011) 118 (21): 954.
https://doi.org/10.1182/blood.V118.21.954.954
Published: 2011
Journal Articles

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

John F. DiPersio, MD, PhD, Robert H. Collins, Jr., MD, William Blum, MD, Marcel P Devetten, M.D., Patrick Stiff, MD, Laurence Elias, MD, Anita Reddy, Ph.D., Jennifer A. Smith, Ph.D., H. Jean Khoury, MD
Journal: Blood
Blood (2009) 114 (22): 633.
https://doi.org/10.1182/blood.V114.22.633.633
Published: 2009
Journal Articles

Leukemic T-PLL Cells Exhibit Short and Narrowly Distributed Telomere Lengths and High Telomerase Activities, Associated with Rapid and Dose-Dependent Cell Death Following Telomerase Inhibition by Imetelstat Sodium.

Gabriela M. Baerlocher, MD, Katia Bassett, PhD, Dirk de Beer, Laurence Elias, MD, Ning F Go, MD, Alexander Roeth, MD
Journal: Blood
Blood (2009) 114 (22): 2647.
https://doi.org/10.1182/blood.V114.22.2647.2647
Published: 2009
Journal Articles

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Asher Alban Chanan-Khan, MD, Nikhil C. Munshi, MD, Mohamad A. Hussein, M.D., Laurence Elias, MD, Fabio Benedetti, M.D., Jennifer Smith, Ph.D., Soo-Peang Khor, Ph.D., Carol A. Huff, MD
Journal: Blood
Blood (2008) 112 (11): 3688.
https://doi.org/10.1182/blood.V112.11.3688.3688
Published: 2008
Journal Articles

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Robert J. Tressler, PhD, Allison C. Chin, Ph.D., Eric J. Feldman, M.D., Kanti R. Rai, M.D., Doug Kornbrust, Ph.D., Calvin B. Harley, Ph.D., Melissa A. Kelly Behrs, Laurence Elias, MD
Journal: Blood
Blood (2006) 108 (11): 2595.
https://doi.org/10.1182/blood.V108.11.2595.2595
Published: 2006
Journal Articles

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.

Nieves Diaz, MD, Eugeny A. Osmanov, MD, Yulia A. Alexeeva, MD, Mikhail Yu Byakhov, MD, Oleg N. Lipatov, MD, Sergey K. Kravchenko, MD, Ilya S. Zuzgin, MD, Felix T. Garzon, MD, Laurence Elias, MD, Philippe Solal-Celigny, MD.
Journal: Blood
Blood (2005) 106 (11): 4783.
https://doi.org/10.1182/blood.V106.11.4783.4783
Published: 2005